# Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation

Study · id `cardio:ct-nct06027307` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06027307](<https://clinicaltrials.gov/study/NCT06027307>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06027307

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 541 participants.

## Technical summary

Registry record NCT06027307. Randomized; quadruple masking; primary purpose treatment. Start 2023-10-25 (actual); primary completion 2027-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 541 participants (enrolled count; ClinicalTrials.gov record NCT06027307, source copy `cardio:ctgov-nct06027307-2025-12-29`, retrieved 2026-10-26)
- Started: 2023-10-25 (actual) (ClinicalTrials.gov record NCT06027307, source copy `cardio:ctgov-nct06027307-2025-12-29`, retrieved 2026-10-26)
- Primary completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT06027307, source copy `cardio:ctgov-nct06027307-2025-12-29`, retrieved 2026-10-26)
- Completion: 2027-08 (anticipated) (ClinicalTrials.gov record NCT06027307, source copy `cardio:ctgov-nct06027307-2025-12-29`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06027307, source copy `cardio:ctgov-nct06027307-2025-12-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06027307-2025-12-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
- Acronym: EVENT
- Condition: Tricuspid Regurgitation
- Condition: Heart Failure With Preserved Ejection Fraction
- Intervention (Drug): Enavogliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Asan Medical Center
- Lead sponsor class: OTHER
- Collaborator: Daewoong Pharmaceutical Co. LTD.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Tricuspid regurgitation (`cardio:tricuspid-regurgitation`)
- Registry lists this organization as the lead sponsor: Asan Medical Center (`cardio:org-asan-medical-center`)
- Registry lists this organization as a collaborator: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 3d35487008503a41f11e6f550e76ac68a78daf577f8e30f943febecd6f9588d1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
